ExPEC4V

BIOLOGICAL3 trials

Sponsors

Janssen Pharmaceutical K.K., Janssen Research & Development, LLC

Conditions

Extraintestinal Pathogenic Escherichia Coli PreventionHealthy

Phase 1

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

CompletedNCT02748967

Janssen Pharmaceutical K.K.Healthy

Start: 2016-04-30End: 2016-08-31Updated: 2016-10-04

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

CompletedNCT03819049

Janssen Research & Development, LLCExtraintestinal Pathogenic Escherichia Coli Prevention

Start: 2019-06-06End: 2024-12-18Updated: 2025-05-25

Phase 2

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

CompletedNCT03500679

Janssen Research & Development, LLCHealthy

Start: 2018-05-09End: 2019-06-11Updated: 2019-11-26

Related Papers

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

npj Vaccines2024-06-1413 citations

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

Open Forum Infectious Diseases2023-08-0126 citations

120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study

Open Forum Infectious Diseases2022-12-012 citations